Rash leading to dose reduction occurred in 5% of patients, and RYBREVANT ® was permanently discontinued due to rash in 0.7% of patients. Toxic epidermal necrolysis occurred in one patient (0.3% ...

J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR ...

Rybrevant plus Lazcluze significantly extends overall survival in EGFR-mutated NSCLC compared to Tagrisso, with benefits continuing beyond the follow-up period. The combination therapy improves ...

As with other drugs, Rybrevant (amivantamab-vmjw) can cause side effects, such as rash, nausea, and fatigue. If you are not able to tolerate side effects of Rybrevant, talk with your doctor or ...

Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European ...

Head-to-head comparison data versus osimertinib showed Rybrevant plus Lazcluze significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell ...

Head-to-head comparison data versus osimertinib showed RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly extended OS in the first-line treatment of patients with locally ...

Halozyme Therapeutics (NASDAQ:HALO) announced Monday that the European Commission has approved an injectable version of Johnson & Johnson’s (NYSE:JNJ) antitumor agent Rybrevant for certain ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved an extension of marketing ...

RARITAN, N.J. - Johnson & Johnson (NYSE:JNJ) disclosed results from its Phase 3 MARIPOSA study, indicating that RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE™ (lazertinib ...